Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection
| العنوان: | Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection |
|---|---|
| المؤلفون: | Hirotaka Arai, Atsushi Naganuma, Takeshi Nihei, Tadashi Ikegami, Hidekazu Kurata, Takaaki Ohtake, Toshiyuki Tahara, Kouichi Miura, Katsuhiko Horiuchi, Ken Sato, Satoru Kakizaki, Shigeo Tano, Toshiro Kamoshida, Norio Isoda, Yukimura Fukaya, Atsuko Soeda, Makoto Iijima, Toshiya Ohtake, Takeharu Asano, Takeshi Hatanaka, Masashi Namikawa, Takeshi Fujieda, Naoki Morimoto, Shunji Watanabe, Takashi Ueno, Takashi Kosone, Toshimitsu Murohisa, Hironori Yamamoto, Yoshinari Takaoka |
| المصدر: | Hepatology Research. 51:51-61 |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Prothrombin time, medicine.medical_specialty, Cirrhosis, Hepatology, Sofosbuvir, medicine.diagnostic_test, business.industry, Hepatitis C virus, medicine.disease, medicine.disease_cause, Gastroenterology, Sofosbuvir/velpatasvir, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, 030220 oncology & carcinogenesis, Internal medicine, Ascites, medicine, 030211 gastroenterology & hepatology, Liver function, Portosystemic shunt, medicine.symptom, business, medicine.drug |
| الوصف: | AIM This study aimed to evaluate the real-world efficacy and safety of 12-week sofosbuvir/velpatasvir (SOF/VEL) treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus (HCV) infection. METHODS A total 72 of patients with Child-Pugh (CP) class B or C were enrolled. We evaluated the sustained virologic response at 12 weeks after the end of treatment (SVR12), adverse events (AEs), and changes in the liver function. RESULTS All participants had genotype 1 or 2 HCV infection. At baseline, the numbers of patients with CP class B and C were 59 and 13, respectively. The overall SVR12 rate was 95.8% (69/72); 94.9% (56/59) in CP class B and 100% (13/13) in CP class C. The serum albumin level, prothrombin time and ascites were significantly improved (P |
| تدمد: | 1872-034X 1386-6346 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52903f616f3d14fcea8b2194824f38e5 https://doi.org/10.1111/hepr.13576 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....52903f616f3d14fcea8b2194824f38e5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1872034X 13866346 |
|---|